ArticleJournal of neuro-oncology2017
Demographics, patterns of care, and survival in pediatric medulloblastoma.
Article in Journal of neuro-oncology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 2 syntheses or guidelines pooled it, 43 citations in OpenAlex.
- Social determinants of health and pediatric cancer survival: A systematic review.Pediatric blood & cancer · 2022Pooled it
- Neuroimaging Biomarkers and Neurocognitive Outcomes in Pediatric Medulloblastoma Patients: a Systematic Review.Cerebellum (London, England) · 2021Pooled it
- Article
- In silico drug sensitivity predicts subgroup-specific therapeutics in medulloblastoma patients.Scientific reports · 2025Article
- Characterizing the Natural History of Pediatric Brain Tumors Presenting with Metastasis.Cancers · 2025Article
- Racial/ethnic disparities in all-cause and cause-specific death among children with malignant central nervous system tumours: a registry-based cohort retrospective analysis.EClinicalMedicine · 2024Article
- Linguistic isolation correlates with length of stay and mortality for pediatric oncology patients in California.Cancer medicine · 2024Article
- The Proteasome Inhibitor CEP-18770 Induces Cell Death in Medulloblastoma.Pharmaceutics · 2024Article
- Opportunities and Advances in Radiomics and Radiogenomics for Pediatric Medulloblastoma Tumors.Diagnostics (Basel, Switzerland) · 2023Review
- Sex differences in methylation profiles are apparent in medulloblastoma, particularly among SHH tumors.Frontiers in oncology · 2023Article
- New Developments in the Pathogenesis, Therapeutic Targeting, and Treatment of Pediatric Medulloblastoma.Cancers · 2022Review
- Population-based analysis of CNS tumor diagnoses, treatment, and survival in congenital and infant age groups.Journal of neuro-oncology · 2022Article
- Surgical outcome of children with medulloblastoma: a retrospective study of a 405-patient series from Children's Cancer Hospital Egypt (CCHE-57357).Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2021Article
- Article
- Primary central nervous system tumor treatment and survival in the United States, 2004-2015.Journal of neuro-oncology · 2019Article
- Simvastatin Induces Apoptosis in Medulloblastoma Brain Tumor Cells via Mevalonate Cascade Prenylation Substrates.Cancers · 2019Article
- National cancer database analysis of outcomes in pediatric glioblastoma.Cancer medicine · 2018Article
- Radiomic-based prognostic score for survival risk-stratification in pediatric medulloblastoma tumors: A multi-institutional study.Neuro-oncology advancesArticle
- Outcomes and patterns of care in a nationwide cohort of pediatric medulloblastoma: Factors affecting proton therapy utilization.Advances in radiation oncologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
We evaluated the American College of Surgeon's National Cancer Data Base (NCDB) to describe current hospital-based epidemiologic frequency, survival, and patterns of care of pediatric medulloblastoma. We analyzed NCDB 1998-2011 data on medulloblastoma for children ages 0-19 years using logistic and poisson regression, Kaplan-Meier survival estimates, and Cox proportional hazards models. 3647 cases of medulloblastoma in those aged 0-19 years were identified. Chemotherapy was received by 79 and 74% received radiation, with 65% receiving both therapies. Those who received radiation were more likely to be older than four, while those who received chemotherapy were more likely to be age four and younger. Variables associated with receipt of neither radiation nor chemotherapy included age at diagnosis of <1 year, female gender, being of race other than black or white, having no insurance, and living in a residential area with a low level of high school graduates. Better overall survival was observed as age at diagnosis increased, in females, and having received radiation. Compared to medulloblastoma, NOS, better survival was observed for those with demoplastic medulloblastoma, with worse survival in those with large cell medulloblastoma. Majority received multi- disciplinary therapy and radiation had the greatest effect on survival. Ages four and under were most likely to receive chemotherapy and least likely to receive radiation. Suboptimal treatment included 17.8% that did not receive chemotherapy, of which 11.8% received neither chemotherapy nor radiation. Disparities associated with medical access were characteristics for not receiving standard treatment, which resulted in poor outcome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.